- Adamis Pharmaceuticals has a strong list of potential catalysts that may have a positive impact on the share price. The recent sell-off has provided me an opportunity to accumulate.
- Adamis has a history of botched opportunities, however, the company's efforts continue to find ways to rally share price around catalysts.
- The company's ZIMHI product candidate is moving closer to an NDA resubmission. If approved, it would be the only injectable naloxone device on the market for the layperson.
- The company's Tempol product candidate for COVID-19 has demonstrated some impressive pre-clinical data that shows potential to be implemented throughout the infection and for long haulers.
For further details see:
Adamis Pharmaceuticals: Upcoming Catalysts Support Speculative Buy